Human Il-12 (recombinant) Uses, Dosage, Side Effects and more
Human Il-12 (recombinant) is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery).
| Trade Name | Human Il-12 (recombinant) |
| Generic | Edodekin alfa |
| Edodekin alfa Other Names | Edodekin alfa, Human il-12 (recombinant), Interleukin 12 (human), Interleukin-12, human, Recombinant Human Interleukin-12, Recombinant interleukin-12 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
